Surrozen Yönetim

Yönetim kriter kontrolleri 3/4

Surrozen CEO'su Craig Parker, Mar2018 tarihinde atandı, in görev süresi 6.67 yıldır. in toplam yıllık tazminatı $ 1.17M olup, şirket hissesi ve opsiyonları dahil olmak üzere 49.8% maaş ve 50.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.18% ine doğrudan sahiptir ve bu hisseler $ 53.29K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4 yıl ve 3.9 yıldır.

Anahtar bilgiler

Craig Parker

İcra Kurulu Başkanı

US$1.2m

Toplam tazminat

CEO maaş yüzdesi	49.8%
CEO görev süresi	6.7yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	4yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Aug 21

CEO Tazminat Analizi

Craig Parker'un ücretlendirmesi Surrozen'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$44m
Jun 30 2024	n/a	n/a	-US$53m
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$1m	US$580k	-US$43m
Sep 30 2023	n/a	n/a	-US$35m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$2m	US$558k	-US$36m
Sep 30 2022	n/a	n/a	-US$50m
Jun 30 2022	n/a	n/a	-US$51m
Mar 31 2022	n/a	n/a	-US$50m
Dec 31 2021	US$4m	US$496k	-US$55m
Sep 30 2021	n/a	n/a	-US$51m
Jun 30 2021	n/a	n/a	-US$45m
Mar 31 2021	n/a	n/a	-US$39m
Dec 31 2020	US$554k	US$441k	-US$33m

Tazminat ve Piyasa: Craig 'nin toplam tazminatı ($USD 1.17M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 647.72K ).

Tazminat ve Kazançlar: Craig 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Craig Parker (62 yo)

6.7yrs

Görev süresi

US$1,165,250

Tazminat

Mr. Craig C. Parker, MBA, serves as Chief Executive Officer and President since March 2018 and Director at Surrozen, Inc., since April 2018. He serves as Director at InduPro, Inc. He joined the Surrozen, I...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Craig Parker	CEO, President & Director	6.7yrs	US$1.17m	0.18% $ 53.3k
Charles Williams	CFO, COO & Corporate Secretary	4yrs	US$675.53k	0.18% $ 53.6k
Li Yang	Executive Vice President of Research	3.8yrs	US$576.73k	0.34% $ 99.6k
K. Christopher Garcia	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Roeland Nusse	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Calvin Kuo	Co-Founder & Member of Scientific Advisor	no data	Veri yok	Veri yok
Esther Jhun	Controller	no data	Veri yok	Veri yok

4.0yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim: SRZN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Craig Parker	CEO, President & Director	6.6yrs	US$1.17m	0.18% $ 53.3k
K. Christopher Garcia	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Roeland Nusse	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Calvin Kuo	Co-Founder & Member of Scientific Advisor	no data	Veri yok	Veri yok
Harold Varmus	Member of Scientific Advisors	no data	US$24.00k	Veri yok
Willard Dere	Member of Scientific Advisors	no data	Veri yok	Veri yok
Christopher Chai	Independent Director	3.6yrs	US$62.05k	0.072% $ 21.4k
Mary Haak-Frendscho	Independent Director	3.7yrs	US$53.05k	0.072% $ 21.4k
Anna Berkenblit	Independent Director	6.3yrs	US$48.05k	0.072% $ 21.4k
David Woodhouse	Independent Chairman of the Board	4.2yrs	US$73.05k	0.072% $ 21.4k
Wen-Chen Yeh	Member of Scientific Advisory Board	1.3yrs	US$716.29k	0.51% $ 150.5k
Bart Williams	Member of Scientific Advisors	no data	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SRZN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Surrozen Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Surrozen, Inc., Annual General Meeting, Jun 05, 2024

Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer

Surrozen, Inc. Announces Management Changes

Recent updates

New major risk - Financial position

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Price target decreased by 45% to US$33.00

Surrozen, Inc. Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen, Inc., Annual General Meeting, Jun 05, 2024

Surrozen, Inc. announced delayed annual 10-K filing

Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis

Surrozen, Inc. announced that it expects to receive $17.549999 million in funding from The Column Group, LLC, Ra Capital Management, Inc.

Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer

Surrozen, Inc. Provides Corporate Update on Clinical Programs

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis

New minor risk - Share price stability

Surrozen, Inc. Announces Management Changes

Nasdaq Grants Surrozen Additional 180 Calendar Day Period to Regain Compliance with the Minimum Bid Price Per Share Requirement for Continued Listing

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely

Surrozen Receives A Written Notice from Nasdaq Regarding Minimum Bid Requirement

Surrozen, Inc. (NasdaqCM:SRZN) announces an Equity Buyback for 1,310,496 shares, for $2.7 million.

Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopathies, Including Diabetic Retinopathy and Diabetic Macular Edema

Price target decreased to US$12.50

Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of Szn-413 in Preclinical Models of Diabetic Retinopathy

Surrozen GAAP EPS of -$0.40 beats by $0.06

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Price target increased to US$19.50

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen, Inc. Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy At the Association for Research in Vision and Ophthalmology Annual Meeting

Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş